Comparative Pharmacology
Head-to-head clinical analysis: BETA HC versus DERMACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETA HC versus DERMACORT.
BETA-HC vs DERMACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BETA-HC (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as prostaglandins and leukotrienes. It also inhibits phospholipase A2 and reduces cytokine production.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response.
1-2 tablets (200-400 mg) orally every 6-8 hours as needed for pain; not to exceed 6 tablets (1200 mg) per day.
Apply a thin film to affected area twice daily (every 12 hours) for up to 2 weeks.
None Documented
None Documented
1.5 hours (beta phase); clinical context: anti-inflammatory effects persist longer than serum levels due to receptor binding and gene transcription
Terminal elimination half-life is approximately 2-3 hours for hydrocortisone, the active component. Due to its short half-life, it requires multiple daily doses for sustained effect.
Renal (approximately 75% as metabolites, <5% unchanged); fecal (approximately 15%)
Primarily hepatic metabolism; metabolites are excreted renally (~75% as glucuronide and sulfate conjugates) and fecally (~25%). Less than 5% of the dose is excreted unchanged in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid